Exact Mass: 474.097387
Exact Mass Matches: 474.097387
Found 34 metabolites which its exact mass value is equals to given mass value 474.097387
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
C23H23ClN2O5S (474.10161380000005)
3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
C23H23ClN2O5S (474.10161380000005)
Rilmazafone
Hyperxanthone|Hypholomin A|Hypholomin-A|Hypholomine A
Ki16425
C23H23ClN2O5S (474.10161380000005)
Vandetanib
C22H24BrFN4O2 (474.10665559999995)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
Cys Cys Cys Phe
C18H26N4O5S3 (474.10652660000005)
Cys Cys Phe Cys
C18H26N4O5S3 (474.10652660000005)
Cys Phe Cys Cys
C18H26N4O5S3 (474.10652660000005)
Phe Cys Cys Cys
C18H26N4O5S3 (474.10652660000005)
Rilmazafone
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D006993 - Hypnotics and Sedatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic
Benzeneacetic acid, 4-chloro-a-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]benzo[b]thien-6-yl]oxy]-, methyl ester
C23H23ClN2O5S (474.10161380000005)
METHYL3,4-DI[[(4-METHYLPHENYL)SULFONYL]AMINO]BENZOATE
6-Chloro-2-oxo-4-methylchromen-7-yl 4-O-beta-D-xylopyranosyl-beta-D-xylopyranoside
N-(4-CHLORO-2-METHYLPHENYL)-2-(N-(3,4-DIMETHOXYPHENYL)PHENYLSULFONAMIDO)ACETAMIDE
C23H23ClN2O5S (474.10161380000005)
BIS(2-(4-AZIDOSALICYLAMIDO)ETHYL) DISULF
C18H18N8O4S2 (474.08923880000003)
5-chloro-N-[(3R)-1-(2-{[2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl]amino}-2-oxoethyl)pyrrolidin-3-yl]thiophene-2-carboxamide
3-[({4-[4-({[(1S)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
C23H23ClN2O5S (474.10161380000005)
3-[({4-[4-({[(1R)-1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
C23H23ClN2O5S (474.10161380000005)
1-(2,1,3-benzothiadiazol-4-ylsulfonyl)-N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)piperidine-3-carboxamide
GluN2B-NMDAR antagonist-1
GluN2B-NMDAR antagonist-1 is an orally active GluN2B-NMDAR antagonist. GluN2B-NMDAR antagonist-1 has neuroprotective activity. GluN2B-NMDAR antagonist-1 can be used for research of ischemic injury[1].